Journal of Clinical & Experimental Dermatology Research
Open Access

Andrea Kovacikova Curkova

Publications

• Research Article
  Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab
  Author(s): Peter Kozub, Andrea Kovacikova Curkova, Maria Zuzulova and Maria Simaljakova Peter Kozub, Andrea Kovacikova Curkova, Maria Zuzulova and Maria Simaljakova
  
  Background: Infliximab is the fastest acting biological agent in psoriasis treatment due to the possibility of intravenous administration and a well-conducted induction phase of treatment (week 0, 2, and 6). Another advantage is the weight-based dosing. However, disadvantages include the risk of infusion reactions and the production of neutralizing antibodies that are responsible for the secondary loss of efficacy. Objectives: To analyze the dynamics of infliximab levels during one maintenance interval as well as the levels of anti-infliximab antibodies in patients with psoriasis treated with infliximab for a period of at least 22 weeks. Methods: We followed 25 patients with psoriasis treated with infliximab for a period of at least 22 weeks at a dose of 5 mg/kg. Based on the clinical picture at the time of blood s.. View More»
  DOI: 10.4172/2155-9554.1000214

  Abstract PDF

Relevant Topics